More than half of women discontinue overactive bladder meds after 6 months


More than half of women prescribed drugs for overactive bladder discontinue treatment after 6 months.

More than half of women prescribed anticholinergic drugs for lower urinary tract symptoms suggestive of overactive bladder discontinued treatment after 6 months, suggesting poor adherence to treatment, researchers report in the December issue of Obstetrics and Gynecology.

Manish Gopal, MD, and colleagues from the University of Pennsylvania in Philadelphia analyzed discontinuation rates of anticholinergic medications used to treat lower urinary tract symptoms using data from 49,419 episodes of anticholinergic therapy from 29,369 women in the United Kingdom.

The researchers found that women discontinued the drugs after a median of 4.76 months. At 6 months, 58.8% of women had discontinued treatment and 77.2% had discontinued after 1 year. At 6 months, 71% had discontinued oxybutynin, 57% had discontinued extended-release oxybutynin, 61% had discontinued tolterodine tartrate, and 54% had discontinued extended-release tolterodine tartrate, the report indicates. Women switched to another medication in 15.8% of episodes. There were an average of 1.65 treatment episodes and an average of 1.54 drug classes prescribed per patient, the authors report.

Gopal M, Haynes K, Bellamy SL, et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112:1311-1318.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.